



La nuova sfida, integrare la medicina di precisione nella medicina della complessità

Enzo Manzato

The terms individualized and personalized medicine have often been used interchangeably with precision medicine in recent literature, thus leading to ambiguity.

Individualized medicine has been defined as a "therapeutic approach tailoring therapy for genetically defined subgroups of patients". Individualized medicine first arose from a study regarding the structure of the genome, mapping genes and sequencing DNA to emphasize genetic differences between patients.

Personalized medicine, which was first mentioned in published literature in 1971, has been defined as a "broad and rapidly advancing field of healthcare that is informed by each person's unique clinical, genetic, genomic and environmental information".



In February 2001, two papers provided the first detailed look at the nearly complete sequence of the human genome.



Human Genome Project

Prevention

Health Promotion

Wellness


The most commonly used definitions of precision medicine in the literature were those developed by:

NIH (2018): an emerging approach to disease treatment and prevention that takes each person's variability in genes, environment and lifestyle into account;

US FDA (2013): the right patient with the right drug at the right dose at the right time;

National Research Council (2011): tailoring of medical treatment to the individual characteristics of each patient.


Precision Medicine — Personalized, Problematic, and Promising



The need for precision medicine is driven by the heterogeneous nature of many diseases

Precision medicine should be viewed as a means of providing the best available health care for a population by identifying the needs and improving the outcomes of individual patients.

Trends in the use of the term 'precision medicine' from 2012 to 2018




Application of the term precision medicine across the top ten clinical specialty areas

Clinical specialty area	Articles, n (%)
Oncology	1060 (33.4)
Respiratory	197 (6.2)
Cardiac/cardiovascular	155 (4.9)
Pathology	146 (4.6)
Clinical neurology	144 (4.5)
Immunology	135 (4.3)
Radiology, nuclear medicine and medical imaging	134 (4.2)
Urology and nephrology	123 (3.9)
Endocrinology and metabolism	112 (3.5)
Psychiatry	100 (3.2)

Precision Medicine — Personalized, Problematic, and Promising

Table 1. Examples of Conditions in Which Precision Medicine Has Been Used.*					
Medical Field	Disease	Biomarker	Intervention		
Cancer	Chronic myeloid leukemia	BCR-ABL	Imatinib ⁴		
	Lung cancer	EML4-ALK	Crizotinib ³		
Hematology	Thrombosis	Factor V Leiden	Avoid prothrombotic drugs ⁵		
Infectious disease	HIV/AIDS	CD4+ T cells, HIV viral load	Highly active antiretroviral therapy⁵		
Cardiovascular disease	Coronary artery disease	CYP2C19	Clopidogrel ⁷		
Pulmonary disease	Cystic fibrosis	G551D	Ivacaftor ⁸		
Renal disease	Transplant rejection	Urinary gene signature	Antirejection drugs ⁹		
Hepatology	Hepatitis C	Hepatitis C viral load	Direct-acting antiviral agents ¹⁰		
Endocrine disease	Multiple endocrine neo- plasia type 2	RET	Prophylactic thyroidectomy ¹¹		
Metabolic disease	Hyperlipidemia	LDL cholesterol	Statins ¹²		
Neurology	Autoimmune encephalitis	CXCL13	Immunotherapy ¹³		
Psychiatry	Alcohol-use disorder	GRIK1	Topiramate ¹⁴		
Pharmacogenomics	Smoking cessation	CYP2A6	Varenicline ¹⁵		
Ophthalmology	Leber's congenital amaurosis	RPE65	Gene therapy ¹⁶		


What is precision medicine?



Eur Respir J 2017; 50:1700391




Associations of the Genetic Scores with the Risk of Cardiovascular Events



Proportional Effect Relative to Effect on LDL Cholesterol Level

Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults

Implications for Primary Prevention




A genomic risk score for coronary artery disease

- Greater association with future coronary artery disease than any single conventional risk factor
- Independent of yet complements conventional risk factors
- Provides meaningful lifetime risk estimates of coronary artery disease
- Quantifiable at or before birth and shows potential for risk screening in early life

Those involved in the development of future precision medicine innovations have a responsibility to ensure they are based on new interdisciplinary methods that take into account all factors that contribute to individual differences in health including genes, environments and lifestyles.

Measuring population ageing: an analysis of the Global Burden of Disease Study 2017



Country ranking


Measuring population ageing: an analysis of the Global Burden of Disease Study 2017

Sensitivity analysis: 2017 equivalent age to global 65-year-olds


	2017 equivalent age to global 65-year-olds (years)			
Country	Sensitivity analysis	Original result	Dif (%)	
Italy	74.5 (73.5, 75)	74.8 (74.3, 75.4)	-0.4%	

Measuring population ageing: an analysis of the Global Burden of Disease Study 2017

Distribution of age-related burden at the global level in 2017 measured in disability-adjusted life year (DALYs)




Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study




Lancet 2012; 380: 37

Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study



Lancet 2012; 380: 37

Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study



2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

2. OVERARCHING RECOMMENDATIONS FOR ASCVD PREVENTION EFFORTS

2.1. Patient-Centered Approaches to Comprehensive ASCVD Prevention

RECOMMENDATIONS

- 1. A team-based care approach is recommended for the control of risk factors associated with ASCVD
- 2. Shared decision-making should guide discussions about the best strategies to reduce ASCVD risk
- **3.** Social determinants of health should inform optimal implementation of treatment recommendations for the prevention of ASCVD

il signor Giovanni...

il malato che contraddistingue il nostro secolo non è affetto da un'unica e definita malattia, acuta e risolvibile nel breve-medio termine, ma è un malato cronico, affetto da più patologie incidenti contemporaneamente

il fenotipo clinico risultante è determinato da fattori biologici (malattiaspecifici) e da determinanti non biologici (status socio-familiare, economico, ambientale, accessibilità delle cure ecc.), che interagiscono fra di loro in maniera dinamica

il signor Giovanni...

la presenza di patologie croniche multiple induce:

- o a consultare numerosi specialisti
- o alla prescrizione di trattamenti farmacologici multipli
- o a ridurre l'aderenza ai trattamenti
- o all'aumento di interazioni farmacologiche e di reazioni avverse
- o all'aumento ingiustificato dei costi sanitari e sociali



Razionale Gli attuali progressi nella diagnostica e nel trattamento delle malattie cardiovascolari, integrati da banche dati e dalla possibilità di un inquadramento genetico del singolo

dola alle caratteristiche fenotipiche e genotipiche.

soggetto, ci consentono di personalizzare la terapia adattan-

a medicina sta ritornando ad essere sartoriale.